Biological Activity & Performance
| Endpoint | Model / source | Reported finding |
|---|---|---|
| Binding affinity | Surface plasmon resonance; Fig. 4a [1,2] | KD: KAT6A 2 nM; KAT5 2.2 µM; KAT7 0.5 µM. |
| Cell growth | EMRK1184 lymphoma cells [1,2] | IC50 0.25 µM; a cellular growth endpoint. |
| Cellular phenotype | Mouse embryonic fibroblasts [2] | Cell-cycle arrest was observed at 1 µM. |
| Animal efficacy | EMRK1184 lymphoma-bearing mice; Fig. 4 [1] | 50 mg/kg intraperitoneally four times daily for 11 days arrested progression in eight of nine treated mice; one nonresponder was reported. Vehicle n = 15. |
| Tolerability | Same mouse study; Extended Data Fig. 10 [1] | No observed weight loss, but leukopenia was reported. This is not evidence of absence of toxicity. |
How to interpret the evidence
The study separates WM-1119 lymphoma results from WM-8014 zebrafish findings. Binding KD, cellular IC50 and animal efficacy are distinct endpoints; no clinical efficacy is established by these experiments.